<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00553969</url>
  </required_header>
  <id_info>
    <org_study_id>0709M15829</org_study_id>
    <nct_id>NCT00553969</nct_id>
  </id_info>
  <brief_title>Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease</brief_title>
  <acronym>DETECT</acronym>
  <official_title>Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease. DETECT (DEtection and Treatment of Early Cardiovascular Disease Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the individual and combined effects of Coreg CR and lisinopril, on
      cardiovascular health as measured by Rasmussen Disease Score (RDS) in a blinded, placebo
      controlled comparison over a 9-month study period. Patients to be randomized will have
      pre-hypertensive blood pressures that do not require anti-hypertensive therapy and at least
      one additional cardiovascular risk factor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  This study will compare the effect of Coreg CR and lisinopril, separately and together,
           on Rasmussen Disease Score in a controlled study with an inactive substance (placebo).

        -  Study patients will have pre-hypertensive (slightly elevated) blood pressures not
           requiring therapy.

        -  Lisinopril is an angiotensin converting enzyme (ACE) inhibitor. Angiotensin is a
           chemical that is made by the body continuously. Angiotensin narrows blood vessels and
           thereby maintains (elevates) blood pressure. When the enzyme is blocked by lisinopril,
           angiotensin cannot be converted into its active form. As a result, blood pressure is
           lowered. Lisinopril is a drug that has been approved for use by the U.S. Food and Drug
           Administration (FDA) and health authorities for the treatment of high blood pressure and
           heart failure.

        -  Coreg CR is a once-a-day heart medication that is part of a class of drugs known as
           beta-blockers. Beta-blockers prevent beta-adrenergic substances such as adrenaline from
           activating parts of the nervous system, including the heart. Beta-blockers therefore
           relieve stress on the heart by slowing heart beat, decreasing the force of heart muscle
           contractions, and reducing blood pressure. Coreg has also been approved by the FDA for
           the treatment of hypertension and various other cardiovascular conditions.

        -  It is possible that the beta blocker could increase the benefits of the ACE inhibitor by
           inhibiting renin production, which is an important step in angiotensin production. These
           two drugs may act together to provide even more protection to blood vessels and the
           heart.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Disease Score (DS) Among the Treatment Groups</measure>
    <time_frame>Baseline and nine months</time_frame>
    <description>Rasmussen Disease Score (RDS) Change From Baseline to 9 Months A score of six or higher on these tests means the patient likely has plaque build-up in the arteries, or atherosclerosis, while a score of three to five suggests that such a problem may be developing. A score of two or less signals a patient is fine but should return in the future for another test. The method detects disease at the earliest moment, before the traditionally used calcium score would show any signs of trouble.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Pre-hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Coreg CR + lisinopril</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Coreg CR + placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lisinopril + placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo + placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carvedilol phosphate</intervention_name>
    <description>Extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Coreg CR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lisinopril</intervention_name>
    <description>tablets, 10mg once daily for 1 month, 20mg once daily for 8 months</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carvedilol phosphate and lisinopril</intervention_name>
    <description>carvedilol phosphate = extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months; lisinopril= tablets, 10mg once daily for 1 month, 20mg once daily for 8 months</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Coreg CR (carvedilol phosphate)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo and placebo</intervention_name>
    <description>capsule once daily for 9 months; dosage unknown</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females &gt; 18 years old with pre-hypertensive or borderline blood pressures
             (systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg) deemed not
             to need antihypertensive therapy. Subjects must also have one additional risk factor
             for cardiovascular disease, including:

          -  LDL &gt; 130 and &lt; 160 mg/dL

          -  HDL &lt; 40 mg/dL

          -  Fasting blood sugar &gt;100 and &lt; 126 mg/dL

          -  Body mass index ≥ 30

          -  Smoker

          -  Family history of premature heart disease or hypertension

        Exclusion Criteria:

          -  Patients with a history of cardiac, cerebral or other vascular events within the
             previous 6 months will be excluded. Other exclusions include background therapy with a
             beta blocker or ACE inhibitor therapy, known or suspected intolerance to beta blockers
             or ACE inhibitors, angiotensin receptor blocker therapy, or diabetes. Pregnant or
             lactating women, and women of child-bearing age who are not using an acceptable form
             of contraception are also excluded from this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay N Cohn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor, University of Minnesota, Cardiology Division</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota, Variety Club Research Center 102</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2007</study_first_submitted>
  <study_first_submitted_qc>November 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2007</study_first_posted>
  <results_first_submitted>December 16, 2013</results_first_submitted>
  <results_first_submitted_qc>December 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 17, 2014</results_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiovascular disease prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Prehypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1 Coreg CR + Lisinopril</title>
          <description>Coreg CR + lisinopril
carvedilol phosphate and lisinopril : carvedilol phosphate = extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months; lisinopril= tablets, 10mg once daily for 1 month, 20mg once daily for 8 months</description>
        </group>
        <group group_id="P2">
          <title>2 Coreg CR + Placebo</title>
          <description>Coreg CR + placebo
carvedilol phosphate : Extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months</description>
        </group>
        <group group_id="P3">
          <title>3 Lisinopril + Placebo</title>
          <description>lisinopril + placebo
lisinopril : tablets, 10mg once daily for 1 month, 20mg once daily for 8 months</description>
        </group>
        <group group_id="P4">
          <title>4 Placebo + Placebo</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 Coreg CR + Lisinopril</title>
          <description>Coreg CR + lisinopril
carvedilol phosphate and lisinopril : carvedilol phosphate = extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months; lisinopril= tablets, 10mg once daily for 1 month, 20mg once daily for 8 months</description>
        </group>
        <group group_id="B2">
          <title>2 Coreg CR + Placebo</title>
          <description>Coreg CR + placebo
carvedilol phosphate : Extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months</description>
        </group>
        <group group_id="B3">
          <title>3 Lisinopril + Placebo</title>
          <description>lisinopril + placebo
lisinopril : tablets, 10mg once daily for 1 month, 20mg once daily for 8 months</description>
        </group>
        <group group_id="B4">
          <title>4 Placebo + Placebo</title>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="23"/>
            <count group_id="B5" value="91"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" spread="13"/>
                    <measurement group_id="B2" value="53" spread="10"/>
                    <measurement group_id="B3" value="53" spread="10"/>
                    <measurement group_id="B4" value="51" spread="13"/>
                    <measurement group_id="B5" value="52.25" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Disease Score (DS) Among the Treatment Groups</title>
        <description>Rasmussen Disease Score (RDS) Change From Baseline to 9 Months A score of six or higher on these tests means the patient likely has plaque build-up in the arteries, or atherosclerosis, while a score of three to five suggests that such a problem may be developing. A score of two or less signals a patient is fine but should return in the future for another test. The method detects disease at the earliest moment, before the traditionally used calcium score would show any signs of trouble.</description>
        <time_frame>Baseline and nine months</time_frame>
        <population>Calculation for change is the value at the later time point minus the value at the earlier time point.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Coreg CR + Lisinopril</title>
            <description>Coreg CR + lisinopril
carvedilol phosphate and lisinopril : carvedilol phosphate = extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months; lisinopril= tablets, 10mg once daily for 1 month, 20mg once daily for 8 months</description>
          </group>
          <group group_id="O2">
            <title>2 Coreg CR + Placebo</title>
            <description>Coreg CR + placebo
carvedilol phosphate : Extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months</description>
          </group>
          <group group_id="O3">
            <title>3 Lisinopril + Placebo</title>
            <description>lisinopril + placebo
lisinopril : tablets, 10mg once daily for 1 month, 20mg once daily for 8 months</description>
          </group>
          <group group_id="O4">
            <title>4 Placebo + Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Disease Score (DS) Among the Treatment Groups</title>
          <description>Rasmussen Disease Score (RDS) Change From Baseline to 9 Months A score of six or higher on these tests means the patient likely has plaque build-up in the arteries, or atherosclerosis, while a score of three to five suggests that such a problem may be developing. A score of two or less signals a patient is fine but should return in the future for another test. The method detects disease at the earliest moment, before the traditionally used calcium score would show any signs of trouble.</description>
          <population>Calculation for change is the value at the later time point minus the value at the earlier time point.</population>
          <units>Overall Rasmussen Disease Score Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.48" spread="1.9"/>
                    <measurement group_id="O2" value="-2.29" spread="2.3"/>
                    <measurement group_id="O3" value="-2.38" spread="2.6"/>
                    <measurement group_id="O4" value="-0.96" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1 Coreg CR + Lisinopril</title>
          <description>Coreg CR + lisinopril
carvedilol phosphate and lisinopril : carvedilol phosphate = extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months; lisinopril= tablets, 10mg once daily for 1 month, 20mg once daily for 8 months</description>
        </group>
        <group group_id="E2">
          <title>2 Coreg CR + Placebo</title>
          <description>Coreg CR + placebo
carvedilol phosphate : Extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months</description>
        </group>
        <group group_id="E3">
          <title>3 Lisinopril + Placebo</title>
          <description>lisinopril + placebo
lisinopril : tablets, 10mg once daily for 1 month, 20mg once daily for 8 months</description>
        </group>
        <group group_id="E4">
          <title>4 Placebo + Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jay N. Cohn, M.D.</name_or_title>
      <organization>University of Minnesota Medical School</organization>
      <phone>612.625.5646</phone>
      <email>cohnx001@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

